A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and tolerability of AB801 in
participants with advanced malignancies, and to determine a recommended AB801 dose for
expansion.